Research to Startup: A different road to impact
Location:Kids Research Centre The Children’s Hospital at Westmead
Think your research could have global impact? Now what?
Hear from researchers who have pursued a different path to gain global impact for their work - building a successful startup business.
Uniseed - a partner of the University of Sydney - provides investment funding to commercialise research-developed technologies that bring significant impact to communities. Uniseed has brought together a panel of researchers turned entrepreneurs that will share the highs and lows of their experience - from discussions with the Tech Transfer Office, leaving the university (or not!), raising capital, forming teams and being in business.
Every journey is different, but all have been fulfilling.
*** NOTE *** To secure your seat we ask for $5 at registration - alll proceeds will be donated to Bandaged Bear.
Our panel includes:
Prof Darren Kelly is a serial entrepreneur and CEO of two start-up companies, Certa Therapeutics which is developing novel drugs for the treatment of kidney fibrosis and OccuRx which is developing novel treatments for retinal eye disease. He was previously Founder and CEO of Fibrotech Therapeutics, a company that developed anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney disease, which was acquired by Shire Plc for US$75 million. Darren is the Associate Dean (Innovation and Enterprise, MDHS) at the University of Melbourne, the Director of Innovation and Enterprise at the Centre for Eye Research Australia (CERA) and Director of Biomedical Research in the Department of Medicine, St Vincent’s Hospital Melbourne.
Dr Michael Bowen is a Group Leader and Senior Lecturer based at the University of Sydney’s Brain and Mind Centre. His expertise is in applying cutting edge cellular and preclinical research techniques to central nervous system drug discovery and drug development. Dr Bowen is a co-founder and Head of Translational Science for Kinoxis Therapeutics Pty Ltd, a University of Sydney spinout company funded by Uniseed that is developing small molecule oxytocin circuit stimulators for the treatment of substance use disorders and dysfunctional social behaviour in CNS conditions. Dr Bowen has received awards including the 2016 Eureka Prize for Outstanding Early Career Researcher, the 2016 International Behavioural Neuroscience Society Early Career Award, and the inaugural NSW Premier’s Prize for Early Career Researcher of the Year in 2015.
Dr Kathryn Sunn is the Commercialisation Manager of Commercial Development and Industry Partnerships (CDIP), at the University of Sydney. Kathryn brings to this role a unique combination of commercial acumen and broad technical expertise. Kathryn has a passionate focus on strategic growth and technology collaborations in the Medical and Life Sciences commercial arena. With over 16 year’s experience in Intellectual Property, IP strategy, commercialisation and business development Kathryn's roles have included two of Australia’s top tier Patent firms and the University of Sydney. Prior to industry participation, Kathryn enjoyed a productive career as a medical researcher working in one of Australia’s leading medical research organisations.
Dr John Kurek is the Biotechnology Investment Manager of Uniseed. John is responsible for identifying new investment opportunities and managing Uniseed’s overall biotechnology and life sciences portfolio. John’s previous roles have included Pharmaceutical Development Manager at BioDiem Ltd, where he was responsible for managing the preclinical, clinical and regulatory aspects of BioDiem’s drug development programs, and Preclinical Development Manager at Amrad Corporation Ltd where he was responsible for the management of preclinical drug development projects.
Come and join us for a unique panel discussion followed by lunch.
Seats are limited so please register early to avoid disappointment.
To reserve your seat a small ticket charge is required - all proceeds will be donated to Bandaged Bear (bandagedbear.org.au ).